CEREVEL THERAPEUTICS
Transforming What is
Possible in Neuroscience
Founded in 2018 through a partnership with Pfizer and Bain
Capital, Cerevel is a clinical-stage biopharmaceutical company
dedicated to unraveling the mysteries of the brain to treat
neuroscience diseases including schizophrenia, Alzheimer's disease
psychosis, epilepsy, panic disorder and Parkinson's disease.
For more information visit, Cerevel.com

Headquartered in Cambridge, MA with morethan 300 employees across the country

Targeted Neurocircuitry
Cerevel unlocks new treatment
opportunities by precisely
identifying and targetingneurocircuitry that underlies agiven neuroscience disease.

Receptor Subtype
Selectivity

DifferentiatedPharmacology

Cerevel is selectively targeting only
receptor subtype(s) related to thedisease physiology, to minimize
undesirable off-target effects while
maximizing activity.

Cerevel designs full and partial
agonists, antagonists, and allostericmodulators that can precisely
fine-tune receptor pharmacology
and neurocircuit activity without
over-activation or over-suppressionof endogenous physiologic range.

Our mission is to become the premier neuroscience company as
we seek to push boundaries, develop solutions and transform thelives of people living with neuroscience diseases.

ing Patients by
Developing a Potential Next-Generation
Antipsychotic with a New MOA
Emraclidine: a highly selective PAM of M4 muscarinic acetylcholine receptors

Psychotic symptoms of schizophrenia are thought to arise
from excess dopamine in a brain structure called thestriatum.1 Current antipsychotics block activity at D2
dopamine receptors.1 While they can be effective,
antipsychotics are associated with many side effects.2

Selective activation of M4 receptors may reduce excess
dopamine signaling in the striatum without blocking D2
dopamine receptors.3 Activation of M4 receptors expressedon cholinergic interneurons reduce acetylcholine release
which in turn, is thought to reduce excess dopamine.3,4Emraclidine is a highly selective
Positive Allosteric Modulator (PAM)of M4 muscarinic acetylcholine
receptors that may reduce psychotic
symptoms associated withschizophrenia without blocking
activity at D2 receptors.5
References
1. Howes OD, et al. Arch Gen Psychiatry. 2012;69(8):776-786.
2. DiBonaventura et al., BMC Psychiatry. 2012;12:20.
3. Yohn SE, et al. Trends Pharmacol Sci. 2022;43(12):1098-1112.
4. Cerevel. Data on file.
5. Krystal JH, et al. Lancet 2022; 400(10369): 2210-2220.
Images created with biorender.com.

EMPOWER Phase II clinical development program
EMPOWER 1 and 2
Screening

Double-blind In Clinic Treatment Period (6 weeks)n=124

RFollow Up

Emraclidine 10 mg (EMPOWER 1) or 15 mg (EMPOWER 2) QD

n=124

End ofTreatment

Emraclidine 30 mg QD

n=124

Placebo
N=372

Screening

Baseline/Day 1

Week 1

Week 2

Week 3

Week 4Week 5

Week 6

Week 10EMPOWER 1 and EMPOWER 2 are part of a comprehensive Phase II program to assess the dose range, efficacy andtolerability of emraclidine in adults with schizophrenia. EMPOWER 3 (not shown) is a 52-week open label extension trial
enrolling rollover and de novo participants.

Scan QR code to learn more about emraclidine
This pamphlet and QR code is intended for HCP audiences only